Skip to main content

Acute Radiation Syndrome

3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Humanetics Corp.
Humanetics Corp.MN - Roseville
2 programs
2
BIO 300 CapsulesPhase 11 trial
BIO 300 Oral PowderPhase 11 trial
Active Trials
NCT00504335Completed24Est. Oct 2007
NCT04650555Completed34Est. Jul 2021
iNtRON Biotechnology
iNtRON BiotechnologyKorea - Gyeonggi
1 program
1
KMRC011 5μg or PlaceboPhase 11 trial
Active Trials
NCT03585803Completed26Est. Nov 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Humanetics Corp.BIO 300 Oral Powder
iNtRON BiotechnologyKMRC011 5μg or Placebo
Humanetics Corp.BIO 300 Capsules

Clinical Trials (3)

Total enrollment: 84 patients across 3 trials

NCT04650555Humanetics Corp.BIO 300 Oral Powder

BIO 300 Oral Powder Safety and Pharmacokinetics

Start: Dec 2020Est. completion: Jul 202134 patients
Phase 1Completed
NCT03585803iNtRON BiotechnologyKMRC011 5μg or Placebo

A Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011

Start: Jun 2018Est. completion: Nov 201926 patients
Phase 1Completed

Safety and Pharmacokinetic Study of BIO 300 Capsules

Start: Jun 2007Est. completion: Oct 200724 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.